반응식
[CH3:1][O:2][C:3]1[CH:8]=[CH:7][CH:6]=[CH:5][C:4]=1[N:9]1[CH2:14][CH2:13][N:12]([CH2:15][CH2:16][CH2:17][C:18]([O:20][CH2:21][C:22]2[CH:31]=[C:30]3[C:25]([CH2:26][CH2:27][C:28](=[O:32])[NH:29]3)=[CH:24][CH:23]=2)=[O:19])[CH2:11][CH2:10]1.[ClH:33]>>[ClH:33].[CH3:1][O:2][C:3]1[CH:8]=[CH:7][CH:6]=[CH:5][C:4]=1[N:9]1[CH2:10][CH2:11][N:12]([CH2:15][CH2:16][CH2:17][C:18]([O:20][CH2:21][C:22]2[CH:31]=[C:30]3[C:25]([CH2:26][CH2:27][C:28](=[O:32])[NH:29]3)=[CH:24][CH:23]=2)=[O:19])[CH2:13][CH2:14]1참가 물질
3
실험 절차
(2-Oxo-1,2,3,4-tetrahydroquinolin-7-yl)methyl 4-(4-(2-methoxyphenyl)piperazin-1-yl)butanoate hydrochloride (39c) (Scheme 7) was prepared from the compound 38c according to the protocol described for the compound 39a (Example 49). The hydrochloride salt 39c gave satisfactory 1H NMR spectral data. White solid, 0.05 g (31%). MS (ESI): m/z=438.2 (M+H+).
출처 및 근거
- ORD 기록
- ord-9c24b41c907a4a5386e87c2ab9273e29
- 출처 데이터셋
- uspto-grants-2012_08
- 특허 번호
- US08247420B2
연결된 노트
불러오는 중…